Company intelligence
Dyne Therapeutics
Focused on delivering functional improvement for people living with genetically driven neuromuscular diseases
About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more https://www.dyne-tx.com/. To view our community guidelines, click here: https://bit.ly/3BYPnpK
Verified activity
Signals from Dyne Therapeutics
6 published signals
Presence & Recognition
Dyne Therapeutics announced that it will present additional 12-month clinical data for z-basivarsen (DYNE-101), currently being studied for the potential treatment of myotonic dystrophy type 1, at the World Muscle Society Congress in Hiroshima, Japan and the American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting in Orlando, Florida.
Reported by Dyne Therapeutics
Presence & Recognition
Dyne Therapeutics is wearing red on World Duchenne Awareness Day to recognize the people at the heart of the Duchenne community.
Reported by Dyne Therapeutics
People
Dyne Therapeutics is hiring for open roles to deliver functional improvement for people living with genetically driven neuromuscular diseases.
Reported by Dyne Therapeutics
Presence & Recognition
Dyne Therapeutics announced that it will present preclinical data for four development candidates for Duchenne muscular dystrophy at the 27th Annual Neuromuscular Study Group Scientific Meeting in San Antonio, Texas.
Reported by Dyne Therapeutics
Presence & Recognition
Dyne Therapeutics asked Dynamos about their motivation to support the Duchenne community and what they want newly diagnosed families to know ahead of World Duchenne Awareness Day 2026.
Reported by Dyne Therapeutics
Presence & Recognition
Dyne Therapeutics is attending the Cantor Global Healthcare Conference on September 11th, the Morgan Stanley 24th Annual Global Healthcare Conference on September 14th, and the Baird 2026 Global Healthcare Conference on September 15th to discuss its pipeline.
Reported by Dyne Therapeutics